Ken Griffin Xenon Pharmaceuticals Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$36.12 - $43.96 $541,800 - $659,400	-15,000 Reduced 47.17%	16,800 $661,000
Q2 2024 Aug 14, 2024	BUY	$36.25 - $43.75 $743,125 - $896,875	20,500 Added 181.42%	31,800 $1.24 Million
Q1 2024 May 15, 2024	SELL	$42.66 - $50.04 $238,895 - $280,224	-5,600 Reduced 33.14%	11,300 $486,000
Q4 2023 Feb 14, 2024	SELL	$28.7 - $46.46 $106,190 - $171,902	-3,700 Reduced 17.96%	16,900 $778,000
Q3 2023 Nov 14, 2023	BUY	$34.16 - $39.73 $235,703 - $274,137	6,900 Added 50.36%	20,600 $703,000
Q2 2023 Aug 14, 2023	SELL	$34.84 - $43.54 $867,516 - $1.08 Million	-24,900 Reduced 64.51%	13,700 $527,000
Q1 2023 May 15, 2023	BUY	$33.46 - $40.35 $287,756 - $347,010	8,600 Added 28.67%	38,600 $1.38 Million
Q4 2022 Feb 14, 2023	BUY	$33.06 - $39.43 $647,976 - $772,828	19,600 Added 188.46%	30,000 $1.18 Million
Q3 2022 Nov 14, 2022	SELL	$30.79 - $39.82 $43,106 - $55,748	-1,400 Reduced 11.86%	10,400 $375,000

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.42B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.